Skip to main content

NextCure, Inc.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

NXTC$5.98-4.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

NextCure, Inc.

Form 10-Q

For the Quarter Ended September 30, 2026

TABLE OF CONTENTS

​ · ​
​​Page
PART I. FINANCIAL INFORMATION
Item 1.Financial Statements1
​Condensed Balance Sheets as of September 30, 2026 (unaudited) and December 31, 20251
​Unaudited Condensed Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2026 and 20252
​Unaudited Condensed Statements of Stockholders’ Equity for the Three and Nine Months Ended September 30, 2026 and 20253
​Unaudited Condensed Statements of Cash Flows for the Nine Months Ended September 30, 2026 and 20254
​Notes to Unaudited Condensed Financial Statements5
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations19
Item 3.Quantitative and Qualitative Disclosures about Market Risk31
Item 4.Controls and Procedures31
PART II. OTHER INFORMATION
Item 1.Legal Proceedings32
Item 1A.Risk Factors32
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds34
Item 3.Defaults Upon Senior Securities34
Item 4.Mine Safety Disclosures34
Item 5.Other Information34
Item 6.Exhibits35
SIGNATURES37

i

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.